Skip to main content
     

Talis conducted a comprehensive in silico assessment comparing the Omicron (B1.1.529) variant published sequences from the GISAID database to its Talis One COVID-19 Test System. The bioinformatics analysis concluded that the Talis One COVID-19 molecular nucleic acid amplification test (NAAT) continues to be able to identify positive cases of COVID-19 caused by Omicron.

Like all viruses, SARS-CoV-2 continues to mutate. In anticipation of this fact, our scientists developed a test with a dual-gene target to ensure accurate results even in the case where one of the targets may become impacted by a mutation. The Omicron variant has been found to show multiple mutations, with a majority occurring on the spike (S) protein. Talis’ molecular NAAT does not rely on the S gene to detect the virus but rather focuses on two other targets: the N and Orf1a/b genes. Individually, >99% of the published Omicron sequences as of December 1, 2021, are a perfect match to at least one of the Talis primer regions, while across both targets, 100% of the sequences match at least one of the primer sets.

The robust multiple target test design helps to ensure that clinicians, researchers and public health officials have an effective tool for COVID-19 testing-even as the genetic makeup of the virus evolves.

Talis will continue surveillance of emerging SARS-CoV-2 variants of concern/interest (VOC/I) by assessing reactivity against genome sequence databases.

To date, Talis has performed assessments looking at the following variants

  • Alpha (B.1.1.7)
  • Beta (B.1.351)
  • Epsilon (B.1.427 and B.1.429)
  • Eta (B.1.525)
  • Iota (B.1.525)
  • Gamma (P.1)
  • Zeta (P.2)
  • Omicron (B.1.1.529)
  • B.1.2
  • B.1.375

Talis One COVID-19 Test System

Central lab-quality SARS-CoV-2 molecular testing for a variety of care settings—less than 30 minutes from sample to results.

Learn More
     

Related Articles

Article
July 18, 2022

Summer Travel 2022 – We’re Still in a Pandemic

In the best of times, summer travel can be a challenge, but for summer 2022, travel may be a bit more chaotic as the COVID-19 pandemic moves through unpredictable ups…
Article
June 15, 2022

Sexually Transmitted Infections and Disease: the Silent Pandemic

Twenty-five years ago, the Institute of Medicine (IOM) published a report on confronting sexually transmitted diseases (STDs) as the “hidden epidemic of tremendous health and economic consequence in the United…
Article
May 13, 2022

COVID-19: It’s Not Over Yet

It’s hard to believe that it’s been more than 2 years since the World Health Organization (WHO) declared COVID-19 a global pandemic on March 11, 2020. At that time, the…
Article
March 16, 2022

COVID-19 Testing for Travel—What Your Patients Need to Know

Whether upcoming travel is for relaxation, business, or a combination of both, testing for COVID-19 is likely an integral part of the trip, especially when traveling by air. There are…

Join Our Newsletter

Subscribe to our newsletter for information about our products and company updates.


    TALIS BIOMEDICAL

    The GenBody COVID-19 Ag Test and the Talis One COVID-19 Test System are for use under Emergency Use Authorization (EUA) only. For In Vitro Diagnostic (IVD) use. For prescription use only. Talis is an authorized distributor of the GenBody COVID-19 Ag test.

    © Talis and Talis One are trademarks of Talis Biomedical Corporation. All Rights Reserved.

    *Additional testing solutions are currently in development and not available for sale.

    References

    1. Data on file with Talis Biomedical. GISAID Database accessed December 1, 2021.